OBJECTIVE: Cardiovascular disease risk among persons with HIV is likely multifactorial, thus testing a variety of available noninvasive vascular ultrasound and other surrogate tests may yield differing results. To address this issue, we assessed multiple metabolic and clinical predictors of endothelial function and carotid intima-media thickness in HIV-infected subjects and compared results with HIV-negative controls. DESIGN: Prospective, cross-sectional study of 50 HIV-infected, healthy adults on stable highly active antiretroviral therapy matched to 50 HIV-negative controls by age, sex, race, and body mass index. METHODS: Flow-mediated vasodilation of the brachial artery, carotid intima-media thickness, dual energy X-ray absorptiometry (HIV-infected subjects), and fasting insulin, lipids, and oral glucose tolerance tests were performed. Results were compared between HIV-infected and control groups. RESULTS: Fifty percent of subjects were African-American with 34% women. Among HIV-infected, mean CD4 cell count was 547 cells/microl; 90% had HIV RNA less than 50 copies/ml. There were no significant differences between HIV-infected and control subjects with regard to brachial artery flow-mediated vasodilation or carotid intima-media thickness. In multivariate analyses of the HIV cohort, independent predictors of endothelial dysfunction (lower flow-mediated vasodilation) were increasing insulin resistance, greater alcohol consumption, and higher baseline brachial artery diameter (P < 0.05); predictors of increased carotid intima-media thickness were hypertension, higher trunk/limb fat ratio, and insulin resistance (P < 0.05). CONCLUSION: In this HIV cohort on modern highly active antiretroviral therapy with well controlled HIV, there were no significant differences with regard to preclinical markers of cardiovascular disease. Insulin resistance was a strong predictor of impaired brachial artery flow-mediated vasodilation and increased carotid intima-media thickness, and may be an important cardiovascular disease risk factor in the HIV population.
OBJECTIVE:Cardiovascular disease risk among persons with HIV is likely multifactorial, thus testing a variety of available noninvasive vascular ultrasound and other surrogate tests may yield differing results. To address this issue, we assessed multiple metabolic and clinical predictors of endothelial function and carotid intima-media thickness in HIV-infected subjects and compared results with HIV-negative controls. DESIGN: Prospective, cross-sectional study of 50 HIV-infected, healthy adults on stable highly active antiretroviral therapy matched to 50 HIV-negative controls by age, sex, race, and body mass index. METHODS: Flow-mediated vasodilation of the brachial artery, carotid intima-media thickness, dual energy X-ray absorptiometry (HIV-infected subjects), and fasting insulin, lipids, and oral glucose tolerance tests were performed. Results were compared between HIV-infected and control groups. RESULTS: Fifty percent of subjects were African-American with 34% women. Among HIV-infected, mean CD4 cell count was 547 cells/microl; 90% had HIV RNA less than 50 copies/ml. There were no significant differences between HIV-infected and control subjects with regard to brachial artery flow-mediated vasodilation or carotid intima-media thickness. In multivariate analyses of the HIV cohort, independent predictors of endothelial dysfunction (lower flow-mediated vasodilation) were increasing insulin resistance, greater alcohol consumption, and higher baseline brachial artery diameter (P < 0.05); predictors of increased carotid intima-media thickness were hypertension, higher trunk/limb fat ratio, and insulin resistance (P < 0.05). CONCLUSION: In this HIV cohort on modern highly active antiretroviral therapy with well controlled HIV, there were no significant differences with regard to preclinical markers of cardiovascular disease. Insulin resistance was a strong predictor of impaired brachial artery flow-mediated vasodilation and increased carotid intima-media thickness, and may be an important cardiovascular disease risk factor in the HIV population.
Authors: D Hürlimann; R Chenevard; F Ruschitzka; M Flepp; F Enseleit; M Béchir; R Kobza; J Muntwyler; B Ledergerber; T F Lüscher; G Noll; R Weber Journal: Heart Date: 2005-03-29 Impact factor: 5.994
Authors: Sudha S Shankar; Michael P Dubé; J Christopher Gorski; James E Klaunig; Helmut O Steinberg Journal: Am Heart J Date: 2005-11 Impact factor: 4.749
Authors: K E Yarasheski; P Tebas; C Sigmund; S Dagogo-Jack; A Bohrer; J Turk; P A Halban; P E Cryer; W G Powderly Journal: J Acquir Immune Defic Syndr Date: 1999-07-01 Impact factor: 3.731
Authors: Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: Hong Chai; Hui Yang; Shaoyu Yan; Min Li; Peter H Lin; Alan B Lumsden; Qizhi Yao; Changyi Chen Journal: J Acquir Immune Defic Syndr Date: 2005-09-01 Impact factor: 3.731
Authors: Anthony Solages; Joseph A Vita; David J Thornton; Jessica Murray; Timothy Heeren; Donald E Craven; C Robert Horsburgh Journal: Clin Infect Dis Date: 2006-03-31 Impact factor: 9.079
Authors: Jessica R Grubb; André Dejam; Jocelyn Voell; William C Blackwelder; Peter A Sklar; Joseph A Kovacs; Richard O Cannon; Henry Masur; Mark T Gladwin Journal: J Infect Dis Date: 2006-04-27 Impact factor: 5.226
Authors: Jeroen P H van Wijk; Eelco J P de Koning; Manuel Castro Cabezas; Jorge Joven; Jos op't Roodt; Ton J Rabelink; Andy M Hoepelman Journal: J Am Coll Cardiol Date: 2006-02-23 Impact factor: 24.094
Authors: Jason V Baker; W Keith Henry; Pragna Patel; Timothy J Bush; Lois J Conley; Wendy J Mack; E Turner Overton; Matt Budoff; John Hammer; Charles C Carpenter; Howard N Hodis; John T Brooks Journal: Clin Infect Dis Date: 2011-08-22 Impact factor: 9.079
Authors: David Dimock; Vijaya Thomas; Anna Cushing; Julia B Purdy; Carol Worrell; Jeffrey B Kopp; Rohan Hazra; Colleen Hadigan Journal: Metabolism Date: 2010-10-13 Impact factor: 8.694
Authors: Jason V Baker; Daniel Duprez; Joshua Rapkin; Katherine Huppler Hullsiek; Harrison Quick; Richard Grimm; James D Neaton; Keith Henry Journal: J Acquir Immune Defic Syndr Date: 2009-09-01 Impact factor: 3.731
Authors: Gretchen E Volpe; Christine A Wanke; Cindy M Imai; Kevin S Heffernan; Jeffrey T Kuvin; Alexandra Mangili Journal: AIDS Res Hum Retroviruses Date: 2014-06-26 Impact factor: 2.205
Authors: Michael I Brener; Wendy S Post; Sabina A Haberlen; Long Zhang; Frank J Palella; Lisa P Jacobson; Adrian S Dobs; Richard T George; Mallory D Witt; Matthew Budoff; Lawrence A Kingsley; Todd T Brown Journal: Am J Cardiol Date: 2015-12-31 Impact factor: 2.778
Authors: Maria Patrizia Carrieri; Camelia Protopopescu; Vincent Le Moing; Philippe Reboud; François Raffi; Sophie Mahy; Perrine Roux; Lise Cuzin; Bruno Spire; Catherine Leport Journal: BMJ Open Date: 2012-11-23 Impact factor: 2.692